Valsartan And Irbesartan In The Treatment Of Patients With Diabetic Nephropathy:Observation Of106Cases

Objective:To prospectively observe the effects of valsartan and irbesartan treatment on trace urinary albumin and blood pressure in patients with diabetic nephropathy. Methods:A prospective observation of106cases of type2diabetes patients with nephropathy was conducted.Subjects were randomly divided into two groups (Group A and Group B).all received basis o hypoglycemic therapy. Group A (n=51)received oral valsartan therapy(80mg/d)while Group B (n=55) received oral irbesartan (150mg/d).Both groups were treated for36weeks with analysis of trace urinary albumin and measurement of balood pressure, glycosylated hemoglobin, total cholesterol, triglyceride, total serum creatinine in every12weeks. Results:(1).Both valsartan and irbesartan effectively reduce trace urinary albumin after three courses of treatment(36weeks).Pre and post-tretment differences were statistically significant (Z=-6.490, P≤0.001) However.when comparing the degree of ruduction betweeen valsartan and irbesartan no statistically significant difference was observed(P>0.05).(2),36weeks valsartan and irbesartan therapy significantly reduced blood pressure(P≤0.05). by three courses of treatment difference was statistically significant (P≤0.05).When measuring at every12weeks,the degree of reduction in systolic blood pressure were different between valsartan and irbesartan (P≤0.05).(3). Both valsartan and irbesartan did"nt reduceglycosylated hemoglobin, total cholesterol, triglyceride, total serum creatinine after three courses of treatment(36weeks).Pre and post-tretment differences were not statistically significant (P>0.05). Conclusion:Both drugs were effective in reducing microalbuminuria and lowering blood pressure in patients with diabetic nephropathy, while irbesartan have an advantage in lowering systolic blood over valsartan.